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II   Abstract 
 
Pancreatic cancer is one of the leading causes of cancer death and one of the most challenging 
solid organ malignancies, due to its aggressiveness, late presentation as advanced disease, high 
rates of operative morbidity and chemoresistance during oncological therapy. Gemcitabine, the 
standard chemotherapy agent for advanced pancreatic cancer patients. Most patients respond to 
the initial treatment, but gradually they become resistant to chemotherapy with disease 
recurrences even after surgery. 
Patients with cancer relapses commonly show resistance to multiple anti-cancer agents of 
different structures and functions within a single class after treated with a member of the class, 
this phenomenon is defined as multidrug resistance (MDR). An important and well-known 
mechanism of tumor MDR is increased drug efflux mediated by several transporters of the ATP-
binding cassette (ABC) superfamily, especially BCRP (ABCG2), MDR1/P-glycoprotein 
(ABCB1) and members of the MRP (ABCC) family. 
Recent studies have shown that the calcium channel blocker, verapamil, when combined with 
standard anticancer chemotherapy drugs, help to overcome resistance through inhibiting the 
transport function of P-glycoprotein, the product of MDR gene, MDR1 or stimulating 
glutathione (GSH) transport by MRP1. 
The side population (SP) represents a small subtype of tumor cells with stem-like properties, 
which can be identified by the flow cytometry-based SP technique, and could be substantially 
eliminated by verapamil during Hoechst 33342 staining. However, little is known about the 
direct effects of verapamil itself on SP cells.  
In this study, we focused on the therapeutic potentiality of verapamil on stem-like SP pancreatic 
cancer cells and investigated if it can act as the chemosensitizer on pancreatic tumor. We 
successfully builded up the orthotopic pancreatic cancer model which was induced by the SP 
subtype sorted cells from the human pancreatic cancer cell line, and most importantly, our results 
suggested that verapamil had an effective anti-tumorigenesis effect on pancreatic cancer either in 
vitro or in vivo. 
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III  Introduction 
  
3.1   Background of pancreatic cancer 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer among 
different primary tumors arising from the pancreas, arising within the exocrine component of the 
pancreas, the term pancreatic cancer is often referred to PDAC. Currently it is the fourth to fifth 
most common cause of cancer-related death in most western industrialized countries, with a poor 
prognosis of  5-year survival < 5%
1, 2
. Unfortunately, this poor survival rate has not improved in 
the past decades, in spite of developed dignostic imaging of the pancreas and aggressive 
therapeutic approaches. The poor prognosis is associated with late diagnosis, high rates of 
operative morbidity and resistance to chemotherapy. 
The risk factors leading to pancreatic cancer may include family history of this disease, smoking, 
obesity, alcoholism, chronic pancreatitis and diabetes mellitus, especially when presented as 
new-onset diabetes mellitus
3
. Strolzenberg-Solomon et al in their nested case-control study of 
more than 500 participants, demonstrated adiponectin concentrations as a risk factor in male 
smokers
4
. 
 
3.2   Treatment of pancreatic cancer 
 
Treatment for pancreatic cancer depends on the stage and location of the cancer as well as on 
patients’age, overall health and personal preferences. The pancreatectomy is the first aid in 
treating cancer that is confined to the pancreas: the Whipple procedure(pancreatoduodenectomy) 
is applied for the tumors located in the head of the pancreas, while the distal pancreatectomy is 
for tumors in the pancreatic tail and body
5
. However, most patients have advanced diseases at the 
time of diagnosis, less than 20% of pancreatic cancer patients are diagnosed with resectable 
diseases
6
.  Furthermore, in unresectable cases, neoadjuvant and postoperative adjuvant therapy 
cases, palliation of symptoms and improvement of survival for patients must be pursued by 
chemotherapies or radiotherapies.  
Over the last decade, pancreatic cancer clinical trials have had few successes. Nucleoside 
analogue, gemcitabine, which remains the standard systemic treatment in unresectable and 
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advanced cases, can prolong survival by 5-6 months
7
. A pivotal paper from 1997 demonstrated 
that a 23.8% clinical benefit and modest improvement with gemcitabine in overall survival (OS) 
of 1.24 months over 5-fluorouracil
8
. In a first-line phase III randomized trial for erlotinib, a 
biologic agent combined with gemcitabine, the 0.33 month advantage in median OS and 6% 
benefit in one-year survival comparing to gemcitabine alone is not generally accepted to be 
clinically relevant
9
. Most recently, the superiority of the combination of gembitabine with nab-
paclitaxel, or a combination of 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) over 
gemcitabine monotherapy has been demonstrated
10, 11
. Despite the value of gemcitabine in 
improving clinical benifit and medial survival, to date, satisfactory outcomes have not been 
achieved with gemcitabine alone or in combination with other cytotoxic drugs
7, 12, 13
. The 
chemoresistant acquisition further limits the chemotherapy efficiency, even with the latest 
generation regimens, the median OS of advanced pancreatic cancer patients is still less than 12 
months
14
. Predicting and overcoming resistance of tumor cells to chemotherapy are the major 
challenges in cancer treatment. 
 
3.3   Gemcitabine metabolism  
  
Gemcitabine (2’, 2’-Difluorodeoxycytidine) is a nucleoside analogue with anticancer activity in a 
variety of solid tumors, particularly pancreatic, bladder and non-small cell lung cancers, as well 
as refractory low-grade non-Hodgkin’s lymphoma and myeloid malignancies15-18. Two general 
classifications of nucleoside transporters have been identified for gemcitabine uptaking into the 
cells: equilibrative nucleoside transporter (ENT) and sodium-dependent concentrative 
mechanisms (concentrative nucleoside transporter, CNT)
19-21
, besides, in pancreatic tumor cells, 
among human ENT1 (hENT1), hENT2, hCNT1, and hCNT3, the major routes for transporting 
gemcitabine into the cells, hENT1 is expressed at high levels, whereas members of the CNT 
family are present only at negligible or at a low functional level
19, 20, 22, 23
.   
Once inside the cell, gemcitabine is phosphorylated by deoxycytidine kinase to its 
mononucleotide in a rate-limiting step, and then subsequently to its active metabolites, 
gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). The cytotoxicity of 
gemcitabine is associated with the incorporation of dFdCTP into DNA and sequential inhibition 
of DNA synthesis, as well as the inhibitor role of dFdCDP on ribonucleotide reductase, to induce 
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depletion of cellular dNTP pools, which ultimately incude the cell apoptosis
22, 24
. The whole 
scheme of gemcitabine transport and metabolism is showed as below: 
 
Figure III.1 Gemcitabine Metabolism.  
Revised from 'Human Equilibrative Nucleoside Transporter 1(hENT1) in pancreatic 
adenocarcinoma'
25
. 
 
3.4   Gemcitabine induced chemoresistance in pancreatic cancer 
 
The development of chemoresistance in human cancers is a major problem in the long-time 
benifited effective chemotherapy. Many forms of pancreatic cancer exhibit initial sensitivity to 
gemcitabine treatment followed by a rapid development of resistance. The mechanism of 
refractoriness to chemotherapy of pancreatic cancers is not fully understood, such resistance can 
be the result of various mechanisms and cellular targets, all of which have been identified to 
influence, as single factors or in combination, resistance to gemcitabine
26-29
. One of the most 
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common mechanisms of drug resistance is the decreased accumulation of drugs within cancer 
cells because of an increased drug efflux (pumping drugs out of cells) or reduced drug 
importation into the cancer cells
14
. 
 
3.4.1   Multidrug resistance phenomenon in pancreatic cancer 
 
One form of drug resistance induced by drug efflux pumps, termed Multidrug Resistance (MDR), 
is a phenomenon characterized by the development of broad cross-resistance to functionally and 
structurally unrelated drugs within a single class after patients are treated with a member of the 
class, which due to enhanced outward transport of drugs mediated by a large super family of 
membrane glycoprotein "ATP-binding cassette (ABC) transporter"
30, 31
.  The super family of 
human ABC transporters has 49 members, which can be divided into 7 subfamilies, named 
ABCA-ABCG based on sequence similarities
32
. Especially members of the ABCB family 
include a 170-KD typical transporter protein (ABCB1), also termed P-glycoprotein (P-gp), the 
product of the human MDR1 gene, and multidrug resistance-associated protein (MRP)
33, 34
 were 
found to correlate with both decreased accumulation of drugs and degree of chemoresistance in 
many different human cancer cell lines
35-37
. In addition, the BCRP (ABCG2) protein, a member 
of the ABCG family has manifested the ability to mediate resistance against several anticancer 
drugs
38
.   
P-gp, presents little in most tissues, nevertheless, it is expressed in some limited normal tissues 
with barrier function, including bile canaliculi of the liver, the proximal tubules of the kidey, the 
capillary endothelial cells in brain, the luminal surface cells of the small and large bowel, adrenal 
gland and pancreatic ductules
39
. In many different cancer types, nearly 40-50% of the patients 
diagnosed with cancer have P-gp up to 100-fold over-expression in the malignant tissues
40-42
. 
The clinical significance of MDR1/P-gp expression in human pancreatic cancer is controversial. 
Sugawara et al. and Bernard research group both failed to demonstrate P-gp expression in 
pancreatic cancer tissues
43, 44
, whereas other studies showed that the expression of MDR1/P-gp is 
common in pancreatic tumors and could potentially contribute the chemoresistant biology of 
pancreatic cancer
7, 13, 45
. 
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What’s more, previous studies have confirmed that gemcitabine is a substrate for MRP5 
(ABCC5) efflux pump
46
, further involved in gemcitabine resistance of pancreatic tumors and 
may contribute to predict the benefit of chemotherapy in patients with pancreatic cancer
29, 47
. 
 
3.4.2   Absence of ENT-1 is associated with gemcitabine resistance 
 
On the other hand, another large family of transporters, the solute carrier (SLC) transporter, 
mediates the transport of a wide spectrum of substrates, including anticancer drugs, into the cell
14
. 
Nucleoside analogue (including gemcitabine) uptake is mediated by two subfamilies of SLC 
transporters, i.e. SCL28 and SCL29, which genes respectively encode CNT proteins and ENT 
proteins. Another point is, although gemcitabine is a substrate of the ATP-dependent effulx 
pump
29
, MRP5 (ABCC5), it is predominantly transported into the cell across cell membranes via 
hENT1, as we mentioned before (in 3.3 Gemcitabine Metabolism). 
Increasing evidences suggested that hENT-1 deficient cells are resistant to cytotoxic nucleosides 
in vitro
48-50
. In pre-clinical studies, hENT1 mRNA levels evaluated by quantitative reverse 
transcription polymerase chain reaction(RT-PCR), were proved to be correlated with the ability 
of gemcitabine to inhibit cells growth as determined by inhibitory concentration 50(IC50) values, 
indicating higher expression levels of hENT1 is directly associated with chemosensitivity
26, 51
. 
To date, hENT1 immunostaining of pancreatic tumor cells, and its RNA expression levels have 
been manifested to serve as a prognostic marker for survival after gemcitabine treatment of 
pancreatic cancer
52, 53
. 
 
3.5   Verapamil as a chemosensitizer in cancer chemotherapy  
  
Since the drug resistance is the major obstacle in treating pancreatic cancer, a means to overcome 
gemcitabine induced chemoresistance is urgently needed. Verapamil is a calcium channel 
blocker clinically utilized to treat cardiac arrhythmias. It has been reported that, verapamil, when 
combined with chemotherapeutic agents, can increase intracellular drug accumulation
54
 and 
retention of chemotherapeutic agents in many human cell lines, including non-small cell lung 
cancer, colorectal carcinoma, leukemia, and neuroblastoma, and the antitumor activity has been 
achieved without enhancing myeloid toxicity
55-58
. More specifically, for example, resistance to 
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vinblastine was partially reversed by verapamil in vinblastine-resistant human leukemic 
lymphoma CCRF-CEM cells and in doxorubicin-resistant B16 murine melanoma cells
59, 60
, as 
measured by short-term cell growth inhibition. A similar potentiation of anthracycline efficacy 
was demonstrated in P388 leukemia cells resistant to daunomycin, in which verapamil 
substantially reduced the concentration of the drug required to eliminate colony formation in soft 
agar
61
. 
The mechanisms involved include verapamil competitively binding to P-gp or stimulating 
glutathione (GSH) extrusion by MRP1 in vitro, which both resulted in an increase in the 
accumulation of drugs by tumor cells
54, 62
. Since MRP1 can transport organic anions, many of 
which are conjugated to the reduced GSH
63
, the transportation of GSH conjugates of 
chemotherapeutic reagents out of cancer cells contributes to the chemotherapy insensitivity
64
. 
Furthermore, phosphorylation of P-gp by PKC (protein kinase C) is necessary for its pumping 
function. Verapamil reverses MDR phenotype by inhibiting the PKC activity. It can also 
sensitize anticancer drugs to tumor cells by increased affinity of the drugs to tumor cells. 
Verapamil reverses MDR by changing subcellular distribution of chemotherapeutic drugs in 
tumor cells; inhibiting P-gp expression by decreasing its mRNA level
65
.  All of these advantages 
can help to overcome tumor cell resistance and enhance the efficacy of chemotherapy. 
 
3.6   Cancer stem cells in pancreatic cancer 
 
Emerging evidences have shown that cancer stem cells (CSCs), a small subset of undifferentiated 
cells within a tumor, with the ability to (i) duplicate themselves and self-renew, (ii) to regenerate 
a phenocopy of the original tumor and drive neoplastic proliferation when transplanted into the 
nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, and (iii) to differentiate 
to some degree into more mature non-stem cell cancer lineages, are responsible for 
tumorigenicity, metastasis and malignancy
66 
, which lead them to be the novel therapy target for 
cancer therapy. The existence of CSCs has been proven in many types of solid tumors including 
acute myelogenous leukemia, breast, brain, gastric cancers, as well as pancreatic cancers
67-71
. 
CSCs markers, such as CD133+, CD133+CXCR4+, CD24+CD44+ESA+, have been applied to 
identify pancreatic CSCs
71, 72
. 
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Side population (SP) is a small subtype of tumor cells with CSCs’ properties and can rapidly 
efflux lipophilic fluorescent dyes to produce a characteristic profile based on fluorescence-
activated flow cytometric analysis
73
.  This is usually measured by efflux of the fluorescent DNA 
binding dye Hoechst 33342 (H33342), with the main, non-SP cells separating according to DNA 
content, and hence cell cycle, using the differential emission spectra of H33342 bound to 
chromatin
73
. The pumps responsible for H33342 efflux, can be attributed to the expressions of 
several ABC superfamily transporters, including MDR1/P-glycoprotein, ABCG2 MRP1 and 
ABCA2
74-77
, these pumps also transport other compounds out of the cell, including chemotoxic 
drugs, such as vinblastine, doxorubicin, daunorubicin, paclitaxel etc
78, that’s why SP cells can 
exhibit increased chemoresistance after in vitro exposure to gemcitabine
79, 80
. Originally, SP with 
the vital dye, Hoechst 33342, was discovered for revealing the multipotential hematopoietic stem 
cells (HSC)
73
, and now SP has been identified in many normal and tumor tissues, moreover, the 
assay has been proposed as a functional method to identify and isolate CSCs
81-84
. 
  
Figure III.2 Murine bone marrow cells stained with Hoechst 33342 and propidium iodide.  
SP cells are known to have highly efficient pumps for the dye Hoechst 33342. The emission 
wavelength shifts to the blue end of the spectrum when the dye concentration is low in the DNA. 
According to different DNA content, cells in specific phase of the cell cycle(G0/G1, S, and G2/M) 
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can be differentiate, since Hoechst dye is able to bind with DNA.( Original graph provided by Dr. 
J. Ellwart). 
 
Goodell et al. has shown that in the presence of the drug verapamil, the SP cells was specifically 
eliminated during Hoechst 33342 staining in hematopoietic stem cells
73
, then verapamil presence 
in the Hoechst 33342 dye as a control technique has been applied in other stem cell lines, such as 
mouse mammary epithelial progenitor cells, spermatogonial stem cells, pediatric tumor cell line, 
prostate, breast, colon, melanoma, esophageal and pancreatic cancer cell lines
85-90
. The 
mechanism involved in the inhibition of SP cells with verapamil, perhaps due to the enriched 
expression of ABC superfamily transporters in SP cells, which can be blocked by verapamil as 
we stated before.  
 
3.7   Aim of the study 
 
Increasing evidences suggested that verapamil can reverse the chemoresistance of many cancer 
cells and keeps a potentiality to generate a synergistic inhibition effect when combined with 
traditional chemotherapeutic reagents. Previously, our laboratory has identified the evidence for 
SP cells in human pancreatic cancer cell line (L3.6pl) as CSCs, which are responsible for 
resistance and metastasis. As little is known about the direct relationship between verapamil and 
SP on human pancreatic cancer, in our study, we focused on the therapeutic potential of 
verapamil on stem-like SP cells both in vitro and in vivo and investigated if verapamil can act as 
a chemosensitizer with gemcitabine in human pancreatic cancer cells in vitro. 
 
 
 
MATERIALS METHODS 
 
14 
 
IV Materials and methods  
 
 
4.1   Materials 
 
4.1.1   Cell lines 
 
4.1.1.1   Human pancreatic cancer cell line L3.6pl and L3.6pl gemcitabine 
resistant variant cell line-L3.6plGres 
 
The human pancreatic adenocarcinoma cell line L3.6pl was yielded from the parental fast-
growing (FG) variant line of the COLO 375 human pancreatic cancer cell lines, which were 
injected into the pancreas of nude mice, harvested hepatic metastases and reinjected into 
pancreas, repeated this cycle for three times. Detailed scheme was showed in the graph 
below
91
(Figure IV.1). L3.6pl was attributed with increased metastatic potential, which was 
associated with increased expression (mRNA and protein) of the proangiogenic molecules basic 
fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and interleukin-8 
(IL-8). L3.6pl cell line maintained the ability of increased motility and invasiveness, which were 
related with increased expression of collagenase type IV (MMP-9) and decreased expression of 
E-cadherin
91
. L3.6pl were cultured in medium with increasing concentrations of gemcitabine, 
starting at 0.5 ng/ml up to 100 ng/ml over 28-month period to develop gemcitabine-resistant cell 
line (L3.6plGres).  
MATERIALS METHODS 
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4.1.1.2   Human pancreatic cancer cell line AsPC-1 
 
The human pancreatic adenocarcinoma cell line AsPC-1 was derived from nude mouse 
xenografts initiated with cells from the ascites of a 62-year-old Caucasian female patient with 
cancer of the pancreas in 1981. The cell line was established by MH Tan
92
, can produce 
carcinoembryonic antigen (CEA), human pancreas associated antigen, human pancreas specific 
antigen and mucin
92
. 
 
4.1.2   Reagents 
 
4.1.2.1   Medium, buffers, solutions for cell culture 
 
DMEM (Dulbecco’s Minimal Essential Medium) 500 mL Invitrogen GmbH, Karlsruhe, Germany 
DMSO (Dimethylsulphoxide)                                            Sigma-Aldrich, Steinheim, Germany 
DPBS-buffer 500 mL                                                          Biochrom AG, Berlin, Germany 
Fetal bovine serum 500 mL                                                Biochrom AG, Berlin, Germany 
MEM vitamin mixture 100 mL                                           PAN Biotech, Aidenbach, Germany 
Figure IV.1 In vivo selection of highly 
metastatic human pancreatic cancer 
cells      
(Original graph from Bruns et al.
91
) 
 
L3.3 cells originated from FG cells 
were injected into the pancreas or 
spleen of nude mice. Liver metastases 
were harvested and treated with DNase 
and collagenase, established in culture. 
Primary cells passaged for 2 or 3 times 
then injected into the speen of pancreas 
of another set of nude mice. After this 
cycle repeated for three times, highly 
metastatic cell line L3.6sl (spleen to 
liver selection) and L3.6pl (pancrea to 
liver selection) were generated. 
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MEM NEAA 100 mL                                                          PAN Biotech, Aidenbach, Germany 
Normocin 20 mL                                                                 InvivoGen, San Diego, USA 
Penicillin/Streptomycin 100 ml (10.000 Units Penicillin/mL, 10 mg Streptomycin/ml) 
                                                                                             PAN Biotech, Aidenbach, Germany 
Trypsin0.05%/EDTA0.02 % in PBS without Ca
2+
 and Mg
2+
 100 mL 
                                                                                             PAN Biotech, Aidenbach, Germany 
Trypan blue (0.4%)                                                              Sigma-Aldrich, Steinheim, Germany 
 
4.1.2.2   Cell culture medium 
 
DMEM (500 ml)                                       plus         10%FCS 
        100 IU/ml Penicillin 
        100 μg/mL Streptomycin  
        2% MEM vitamin mixture 
        2% MEM NEAA 
1 ml Normocin was added to the above mixed culture media as a "routine addition" to prevent 
mycoplasma, bacterial and fungal contaminations in small or large scale of animal cell cultures. 
 
4.1.2.3   Cell storage medium 
 
90% FCS                                      plus         10%DMSO 
 
4.1.3   Cell culture materials 
 
  5 ml coster stripette       Corning Inc, New York, USA 
10 ml coster stripette       Corning Inc, New York, USA 
25 ml coster stripette        Corning Inc, New York, USA 
25 cm
2
 nunc sterile tissue culture flasks           Thermo Fisher Scientific Inc, Denmark 
75 cm
2
 nunc sterile tissue culture flasks          Thermo Fisher Scientific Inc, Denmark 
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150 cm
2
 nunc sterile tissue culture flasks        Thermo Fisher Scientific Inc, Denmark 
15 ml Centrifuge tubes                          TPP, Switzerland 
50 ml polypropylene conical tubes                              BD Bioscience Europe, Belgium 
6, 12, 24 and 96-well nunc delta surface culture plates 
         Thermo Fisher Scientific Inc, Denmark 
12 and 24-well companion plate notched for use with cell culture insert 
         BD Dicknson Labware, USA 
Nunc cryotube (2.0 ml)      Thermo Fisher Scientific Inc, Germany 
Eppendorf safe-lock tubes (0.6 ml, 1.5 ml, and 2.0 ml) 
        Eppendorf AG, Hamburg, Germany 
Hemacytometer and cover-slip (Cell counting chambers) 
          r er-  r ,  ermany 
 
4.1.4   Technical equipments 
 
 
Automatic Tissue Processors Model 2065/2   MDS Group GmbH, Buseck, Germany 
Automatic pipettes       Gilson, Middleton, WI, USA 
Axioskop 40, AxioCam MRc5 Digital fluorescence 
        Carl Zeiss AG, Oberkochen, Germany 
Casting stand        Bio-Rad Laboratories GmbH, Munich, 
        Germany 
Centrifuge 5417R       Eppendorf AG, Hamburg, Germany 
Centrifuge Rotina 420R     Andreas Hettich GmbH & Co. KG, 
        Tuttlingen, Germany 
CO2 incubators       Heraeus, Rodenbach, Germany 
Digital precision scale      KERN & Sohn GmbH, Germany 
Dryer cabinet       Heraeus Instruments, Hanau, Germany 
FACS Calibur       BD, Biosciences, USA 
Freezer -20°C       Siemens AG, Germany 
MATERIALS METHODS 
 
18 
 
Freezer -80°C       Heraeus, Hanau, Germany 
Fridge 4°C        Siemens AG, Germany 
Hand tally counter       Carl Roth GmbH, Karlsruhe, Germany 
Herasafe EN12469 2000 Class II safety cabinet   Thermo Fisher Scientific Inc, Germany 
Histomat 2065/2LZ/Di      Bavimed Laborgeräte GmbH, Birkenau, 
        Germany 
Leica RM2255, Fully Motorized Rotary Microtome 
        Leica Microsystems, Germany 
LSR II flow cytometry      BD, Biosciences, USA 
Liquid nitrogen tank       MVE, New Prague, MN, USA 
Microwave oven       Siemens, Germany 
Millipore-Anlage MilliQ A10    Millipore Corporation, Bilerica, USA 
MoFlo high speed sorter      DAKO Cytomation, Glostrup, Denmark 
Phase contrast microscopy      Carl Zeiss GmbH, Germany 
Philips Infrared Lamp      Philips Consumer Lifestyle, Drachten, 
        Netherlands 
PH -Meter       Hanna Instruments Ltd, Bedfordshire, UK 
Thermo Scientific Heraeus incubator    Thermo Fisher Scientific Inc, Germany 
TECAN GENios Plus ELISA reader    TECAN, Salzburg, Austria 
Trans-Blot SD Semi-Dry Transfer chamber   Bio-Rad Laboratories GmbH, Munich, 
        Germany 
Vortex        IKA Works, Wilmington, NC, USA 
Warmer incubator 37 °C     Binder GmbH, Tuttlingen, Germany 
Warmer incubator 60 °C     Memmert GmbH & Co. KG,  
        Schwabach, Germany 
Waschmaschine Professional G7883    Miele& Cie. KG, Gütersloh, Germany 
Water bath        GFL, Burgwedel, Germany 
 
4.1.5   Materials for cell proliferation and cytotoxity assay  
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Gemcitabine (Gemzar)      Lilly Deutschland GmbH, Germany 
Verapamilhydrochloride(verapamil)    Sigma-Aldrich GmbH, Steinheim, Germany 
Cell counting kit-8 (CCK-8)      Dojindo Laboratories, Japan 
 
4.1.6   Materials for colony formation assay, western blot, flow cytometry 
(including apoptosis assay), and immunohistochemistry   
 
2-Mercaptoethanol       Sigma-Aldrich GmbH, Steinheim, Germany 
4% paraformaldehyde      Pathology LMU, Germany 
7-AAD        BD phamingen, USA 
Acryl-bisacrylamide 30%       Bio-Rad Laboratories GmbH,  
        Hercules, USA 
Albumin from bovine serum (BSA)                                     Sigma-Aldrich GmbH,Steinheim, Germany 
Ammoniumpersulfat (APS)       Carl Roth GmbH und Co. KG, Karlsruhe, 
        Germany 
Annexin V-FITC kit       Miltenyi Biotec GmbH,  
        Bergisch Gladbach, Germany 
Avidin/Biotin blocking kit       Vector Laboratories, CA, USA 
BCA protein assay reagent kit     Pierce, Rockford, USA 
Biotinylated secondary antibody     Vector Laboratories, CA, USA 
Bromphenolblue       ICN Biomedicals GmbH, Frankfurt,   
         Germany 
Citrat acid       Merck, Darmstadt, Deutschland 
Complete Lysis-M      Roche applied science, Mannheim,    
         Germany 
Crystal violet        Sigma-Aldrich GmbH, Steinheim, Germany 
DAPI in mounting medium       Vector Laboratories, CA, USA 
ECL western blotting detection system     Amersham Biosciences, Germany 
Ethanol 70%, 80%, 96%, 100%      CLN GmbH, Niederhummel, Germany 
Eosin        Merck, Darmstadt, Germany 
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FCR blocking reagent (human)      Miltenyi Biotec GmbH, Germany 
Hoechst 33342       Sigma-Aldrich, Steinheim, Germany 
Hydrochloride       Merck, Darmstadt, Germany 
Hydrogen peroxide 30% (H2O2)      Merck, Darmstadt, Germany 
In situ cell death detection kit (TUNEL assay)    Roche, Penzberg, Germany 
IgG1-FITC mouse isotype      Miltenyi Biotech, Bergisch Gladbach,   
         Germany 
Isopropanol       Merck, Darmstadt, Germany 
Kaiser’s glycerolgelatine       Merck, Darmstadt, Germany 
Liquid DAB+ substrate chromogen system      Dako, CA, USA 
Low fat milk powder        Carl Roth GmbH and Co. KG,    
          Karlsruhe, Germany 
Mayer’s hemalum solution        Merck, Darmstadt, Germany 
Methanol       Merck, Darmstadt, Germany 
Monoclonal mouse anti-β- actin antibody     Sigma-Aldrich GmbH, Germany 
Monoclonal mouse anti-P-glycoprotein antibody (C219)  
        Calbiochem, Darmstadt, Germany 
Monoclonal rabbit anti-Ki67 antibody (ab16667)    Abcam, UK 
Neo-Clear
®
 (Xylene substitute)       Merck, Darmstadt, Germany 
Normal rabbit serum         Vector Laboratories, CA, USA 
Normal goat serum         Vector Laboratories, CA, USA 
Polyclonal goat anti-mouse/ rabbit immunogluobulins HRP 
         Dako, Glostrup, Denmark 
Polyclonal rabbit anti-h-ENT1 antibody (ab48607)    Abcam, Cambridge, UK 
Polyclonal rabbit anti-CD31 antibody (ab28364)     Abcam, Cambridge, UK 
Polyvinylidene difluoride membranes (PVDF)     Amersham, Braunschweig, Germany 
Propidium iodide        BD phamingen, USA 
Protease/phosphatase inhibitors     Roche, Mannheim, Germany 
Protein-Leiter          Genscript corporation, Picataway, USA 
Restore western blot stripping buffer     Pierce, Rockford, USA 
Sodium chloride        Merck, Darmstadt, Germany 
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Sodiumdodecylsulfat(SDS)        Sigma-Aldrich, Steinheim, Germany 
Target retrieval solution 10×       Dako, CA, USA 
Tetramethylethylendiamin(TEMED)      Sigma-Aldrich, Steinheim, Germany 
TRIZMA Base        Sigma-Aldrich, Steinheim, Germany 
TRIZMA hydrochloride       Sigma-Aldrich, Steinheim, Germany 
Triton
®
 X-100        Sigma-Aldrich, Steinheim, Germany 
Tri-sodium-citrat-dihydrat         Merck, Darmstadt, Deutschland 
Tween 20        Serva Elektrophoresis GmbH,    
            Heidelberg, Germany 
Vectastain
®
 ABC kit           Vector Laboratories, CA, USA 
Verapamilhydrochloride (verapamil)     Sigma-Aldrich, Steinheim, Germany 
Flow cytometry tubes       BD Bioscience Europe, Belgium 
BD Falcon 5 ml polystyrene round-bottom tubes (REF 352052) 
BD Falcon 5 ml polystyrene round-bottom tubes with cell strainer cap (REF 352235) 
BD Falcon 5 ml polypropylene round-bottom tubes with cap (REF 352063)  
 
4.1.7   Solution and Buffer 
 
4.1.7.1   Solution for cell culture  
 
Verapamil solution 
Dissolved in H2O (dest.) to 5 mM stock, kept in 4°C for six months. 
 
Gemcitabine solution 
Dissolved in PBS buffer to 10 mg/ml stock, and kept in 4°C for one week. 
 
Hoechst 33342 solution  
Dissolved in H2O (dest.) to 1 mg/ml stock, aliquot, kept in – 20°C. 
 
1% crystal violet solution 
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0.5 g crystal violet dissoved in 50 ml 100% ethanol, kept in the room temperature, avoiding light. 
  
4.1.7.2   Solution and Buffer for SDS-PAGE and Westernblot 
 
Separating buffer 
TRIZMA Base    90.8 g 
SDS      1 g 
H2O (dest.)   ad         500 ml  
Adjust pH to 8.8, kept at 4 °C. 
 
Tris-HCl-Buffer 
Tris       1 M 
pH 6.8 
 
Tris       1.5 M 
pH 8.8 
 
SDS Running buffer 10 × 
TRIZMA Base    30.3 g 
Glycin     144.0 g 
SDS     10 g 
H2O (dest.)   ad 1000 ml 
kept at 4 °C, before application, diluted to 1 × SDS Running buffer as following: 
100 ml 10 × SDS Running buffer + 1000 ml H2O (dest.) 
 
Transfer-buffer 
1× SDS Running buffer   400 ml 
Methanol      100 ml 
 
10× TBS-buffer 
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TRIZMA Base      24.2 g 
NaCl        80 g 
H2O (dest.)   ad   1000 ml 
Adjust pH to 7.6 
 
TBST 1× (0.1% Tween) 
10× TBS-buffer      100 ml 
H2O (dest.)   ad   1000 ml 
Tween 20           1 ml 
 
5 × Lade-Buffer 
0.5 M Tris HCl pH 6.8         2 ml 
Glycerol        3.2 ml 
20 % SDS        1.6 ml 
2-Mercaptoethanol          0.8 ml 
1 % Bromphenolblue         1.6 ml 
H2O (dest.)       6.8 ml 
aliquot, kept in – 20°C. 
 
10 % APS 
Dissolved in H2O (dest.), aliquot, kept in – 20°C. 
 
Strip-buffer 
TRIZMA hydrochloride   10.32 g 
SDS           20 g 
2-Mercaptoethanol                  7 ml 
H2O (dest.)    ad   1000 ml 
Adjust pH to 6.7 
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4.1.7.3   Solution and Buffer for Immunohistochemistry 
 
Tris-HCl-buffer 
TRIZMA Base   6.85 g 
TRIZMA Hydrochloride    0.9 g 
Sodium chloride   8.75 g 
H2O (dest.)    ad       1000 ml 
Adjust pH to 7.5  
 
Tris buffered saline (TBS) buffer, 10× 
Tris-HCl       1 M 
NaCl     1.5 M  
Adjust pH to 7.4 
 
PBS wash buffer 1× 
NaCl     140 mM 
KCl      2.7 mM 
Na2HPO4            10 mM 
KH2PO4     1.8 mM 
High purity dH2O, adjust pH to 7.4  
 
Citrat-Buffer  
Solution A:    Citrat acid (C6H6O7*H2O)         10.5 g dissolved in 250 ml ddH2O 
Solution B:    Tri-Sodium-Citrat-Dihydrat (C6H5O7Na3 )   
       29.41 g dissolved in 500ml ddH2O 
18 ml Solution A + 82 ml Solution B, add ddH2O to 1 L. 
Kept at 4°C for longer time. 
 
4.1.8   Materials for animal experiments 
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4.1.8.1   Animals 
 
Bagg-albino/c (Balb/c) nu/nu male mice   Charles River, Sulzfeld, Germany 
(8-10 week old, 20-22 g) 
 
4.1.8.2   Surgical materials 
 
BODE Cutasept
®
 F       Bode Chemie, Hamburg, Germany 
Disposable scalpels       Feather Safety Razor Co., Japan 
Forceps        Dosch GmbH, Heidelberg, Germany 
Hypodermic needle (30G)      B-Braun, Melsungen, Germany 
Needle holder       Dosch GmbH, Heidelberg, Germany 
Normal saline (0,9%)      B-Braun, Melsungen, Germany 
Q-tips (cotton applicator)      NOBA, Wetter, Germany 
Rotilabo
®
-embedding cassettes     Carl Roth GmbH, Karlsruhe, Germany 
Scissors, sharp / blunt      Dosch GmbH, Heidelberg, Germany 
Syringe (1 ml, 5 ml)       BD Plastipak
TM
, Madrid, Spain 
Thread with needle USP 4/0 Seralon
®
    Serag-Wiessner AG, Naila, Germany 
 
4.1.8.3   Medicine 
 
Growth Factor Reduced (GFR) BD Matrigel
TM
 Matrix10 mL 
        354230, BD Biosciences, USA 
Ketaminhydrochlorid (Ketavet
®
) 100 mg/mL   Pfizer Pharmacia GmbH,  
        Berlin Germany 
Xylazinhydrochlorid, Xylazin (Rompun
®
) 2% 25 mL 
        Bayer Healthcare,  
        Leverkusen, Germany 
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4.1.9   Software 
 
Adobe Acrobat 7.0 Professional     Adobe Systems Inc., USA 
Axio Vision 4.4       Carl Zeiss GmbH, Germany 
EndNote X7 (MAC Version X7)     Thomson Reuter, CA, USA 
FlowJo software      Treestar Inc., Ashland, USA 
Graphpad Prism 5.0      GraphPad Software, Inc., USA 
Image-Pro Plus 5.0       Media Cybernetics, Inc., USA 
Microsoft Office 2010 (Word, Excel, Powerpoint)   Microsoft Corporation, USA 
SPSS Statistics 19       SPSS STATISTICS Inc., USA 
SoftMax
®
 Pro       Molecular Devices Corp., USA 
 
4.2   Methods 
 
4.2.1   Cell culture conditions 
 
 
All kinds of cell lines used in this study were incubated at 37°C under 5% CO2. The humidity of 
the incubator was 95%. Cells were keeping cultivated with the medium changed twice a week.  
 
4.2.2   Determination of cell number 
 
100 μL of single cell suspension was gently mixed with an equal volume of 0.4% trypan blue. 10 
μL of the above mixture cell suspension was aspirated into the space between the glass cover-lip 
and hemacytometer chamber. Then the number of viable (transparent unstained) cells were 
counted in an area of 16 squares using a hand tally counter.  After summing up all 4 sets of 16 
corner squares, the total number was divided by 4 to calculate the average number, and then 
multipled by 2 (to adjust for the 1:2 dilution factor with trypan blue). Finally, the concentration 
of cells per mL was obtained as multiplying by 1 × 10
4
 (the formula listed below). 
Cell number per mL = (four blue-region unstained total cell number / 4) × 2 × 10
4 
MATERIALS METHODS 
 
27 
 
4.2.3   Storage and recultivation of the cells 
 
4.2.3.1   Storage of the cells 
 
The cells determined by the above mentioned method were stored as one to four million cell 
portions in 1.0 mL cell storage medium per cryotube. The 1.0 mL cell storage medium is 
composed of 900 μL FCS and 100 μL DMSO. DMSO is a cryprotective agent which can 
minimize the cellular injury by freezing and thawing procedures such as intracellular ice crystals 
and osmotic effects. The tubes are moved to a gradually temperature-decreasing tank and then 
kept in -80°C freezer. After 72 hours, the tubes were moved to a liquid nitrogen tank for long-
time storage. 
 
4.2.3.2   Recultivation of the cells 
 
Before recultivation of the cells, the culture medium was first aspirated into the cell culture flask 
and kept in the incubator. The frozen tubes were taken out of the liquid nitrogen tank and 
immediately put into the 37°C prewarmed water bath for 1-2 minutes until complete thawing of 
the cells. The cells were then added into the cell culture flask with medium. After 24 hours 
culturing in the incubator, the medium was changed to avoid toxic effects of the remaining 
DMSO. 
 
4.2.4   Isolation of SP- and non-SP-cell fractions from L3.6plGres and AsPC-1 
cell lines 
 
L3.6plGres and AsPC-1 cell lines were prepared for SP cells isolation when they reach 60-70% 
confluence. SP- and non-SP-cell fractions were identified and isolated using a modified protocol 
described by Goodell et al.
73
.  Briefly, 10
6
/ml cells were re-suspended in DMEM containing 2% 
fetal bovine serum and labeled with Hoechst 33342 at a concentration of 2.5 μg/ml for 60 minutes 
at 37 °C water bath, either alone or with 225 μM verapamilhydrochloride (verapamil). After 
60min-staining, the cells were centrifuged at 4°C and 300g for 5min and resuspended in ice cold 
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PBS, containing 2% fetal bovine serum, passed through a 40um mesh filter and maintained at 
4 °C in the dark until flow cytometry analysis for sorting or further cell surface marker staining. 
Cells were counterstained with 10 μg/ml propidium iodide to label dead cells, then analyzed by 
BD-LSRII flow cytometer and FlowJo software or sorted by MoFlo with the Summit 4.3 software. 
Hoechst dye was excited at 355nm (UV), and the fluorescence was measured at two wavelengths 
using a 450/50 nm (blue) band-pass filter and a 670/30 nm (red) long-pass edge filter. Isolated SP 
cells from L3.6plGres and AsPC-1 were kept on ice for further application. After isolation, SP- and 
non-SP-cell fractions were used for the following in vitro assays and in vivo orthotopic pancreatic 
cancer mice model.   
 
4.2.5   Cell viability, proliferation assay and IC50 determination 
  
The trypan blue staining was used for the cell viability measurement. The dye Trypan Blue stains 
dead cells with membrane defects, thus, living and dead cells can be distinguished by their ability 
to exclude the blue dye under the phase contrast microscopy. The cell viability was calculated 
followed the formula displayed below: 
 Cell viability = unstained cells/(unstained + trypan blue stained cells) × 100% 
Cell proliferation was measured using the Cell Counting Kit-8. According to the manufacture’s 
instructions, 5,000 - 8,000 cells/well plated in the 96-well plate were grown over night, treated for 
24 hours with specific chemotherapeutics (gemcitabine or verapamil) and read out afterwards 
using VersaMax tunable microplate reader and Softmaxpro 5.2 for data analysis. 
 
 
4.2.6   Apoptosis assay 
 
Cell apoptosis assay were applied with the Annexin V-FITC kit following its specification. After 
determination of the cell number, wash 10
6
 cells in 1 mL of 1× binding buffer and centrifuge at 
300 g for 10 minutes. Aspirate supernatant completely. Resuspend cell pellet in 100 uL of 1× 
binding buffer per 10
4
 cells. And then add 10 uL of Annexin V-FITC per 10
6
 cells, mix well and 
incubate for 15 minutes in the dark at room temperature. Afterwards, we wash cells with 1× 
binding buffer, centrifuge and aspirate supernatant completely. Resuspend cell pellet in 500 uL 
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of 1× binding buffer per 10
6
 cells. Add 5 uL of PI solution immediately prior to analysis with by 
BD-LSRII flow cytometer and FlowJo software. Experiments were repeated three times. 
 
4.2.7   Colony formation assay 
 
  
We seeded 500 cells/well with 2 ml required DMEM medium into 6-well plates ensuring that all 
the cells seeded are single cells, changed medium twice per week, stopped the assay when the 
colonies are clearly visible even without looking under the microscope (each single colony 
should composed of at least 50 cells). At the end we stained the colonies with 0.1% crystal violet 
and counted them.  
 
4.2.8   Western Blot assay 
 
4.2.8.1   Preparation of proteinlysates 
 
After wash the cells with cold PBS for three times, they were directly lysed in Complete Lysis-M 
buffer supplemented with protease/phosphatase inhibitors for 10 min on ice, centrifuged at 
14000 g at 4°C for another 10 min, then the supernatant fluid were collected and kept at -20°C. 
 
4.2.8.2   Determination of the protein concentration 
 
Protein concentrations were measured using the BCA protein assay. Mix 5 μl preprepared 
proteinlysates or 5 μl standard protein samples in 45 μl ddH2O in a 96-well plate, then add 50 μl 
BCA working reagent (1 μl solution B + 49 μl solution A) to each well, mix properly, incubate 
for 30 min at 37°C, cool down to room temperature and measure OD of all samples at 562 nm 
within 10 minutes, using TECAN GENios plus ELISA reader, and analyse the data with 
SoftMax Pro. 
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4.2.8.3   SDS-Polyacrylamidgelelectrophorese PAGE 
 
The cell lysates were mixed with 5 × loading buffer, boiled at 95 °C for 5 min and centrifuged at 
16,000 g at 4 °C for 5 min, the samples for monoclonal anti-P-gp mouse antibody detection were 
not boiled based on the specifications. The different protein samples (up to 20 μg) were loaded 
onto sodium dodecyl sulfate-polyacrylamide gels for electrophoresis. 6μl protein ladder was 
loaded as molecular weight standard. The electrophoresis condition was 20 mA per gel for 120-
150 min at RT. Different concentration of separating gels and 5% stacking gels were prepared as 
following: 
 
12% separating gels (for detecting polyclonal rabbit anti-hENT1 antibody) 
Components        Volume (ml) 
Separating buffer             2.95 
Acryl-bisacrylamide 30%                  2.0 
APS 10%              0.05 
TEMED              0.002 
 
8% separating gels (for detecting monoclonal mouse anti-P-gp antibody) 
Components        Volume (ml) 
Separating buffer             3.65 
Acryl-bisacrylamide 30%                  1.3 
APS 10%              0.05 
TEMED              0.003 
 
5% stacking gels for denaturing SDS-PAGE 
Components        Volume (ml) 
H2O (dest.)                    0.68 
Acryl-bisacrylamide 30%                  0.17 
1M Tris (pH 6.8)              0.13 
SDS 10%              0.01 
APS 10%              0.01 
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TEMED              0.001 
 
4.2.8.4   Transfer the protein to PVDF membrane   
 
After separation, proteins were transferred to a PVDF membrane in a semidry transfer chamber. 
Before transfer, the membrane was immersed in 100% methanol for several minutes, and the 
equal size of blotting paper were immersed thoroughly in transfer buffer. The transfer took place 
in a semidry transfer unit at a constant flow of 150 mA per gel (maximum voltage controlled 
below 25 V) for 60 min at RT.  
 
Transfer structure:  
Cover plate (cathode plate)  
Three layers of gel blotting paper  
SDS-polyacrylamide gel  
PVDF membrane  
Three layers of gel blotting paper  
Bottom plate (anode plate) 
 
4.2.8.5   Detection of protein expression 
 
Sequentially after transferring the membranes were blocked with 5% milk in TBST for 2 hours at 
RT, then incubated with respective first antibody according to the manufacturer’s instructions at 
4°C overnight on a rotating platform, washed 3 times with TBST 15min each time, then 
incubated with corresponding horseradish peroxidase (HRP)-conjugated secondary antibody at 
RT for 2 hours, following another washing procedure again and finally detection using an 
enhanced chemiluminescense system. Afterwards the membranes were used for ß-actin to ensure 
equal protein amounts. For detection of ENT1 protein, the anti-ENT1 antibody was used at 1:500 
dilution in 5% BSA-TBST buffer. For P-gp detection, the monoclonal mouse C219 antibody was 
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used at 1:100 dilution in 7.5% skim dried milk-PBST buffer. This antibody recognizes the two 
renal P-gp isoforms
93
. 
 
4.2.9   Orthotopic pancreatic cancer mouse model 
 
4.2.9.1   Animals 
 
The 8 to 10-week old, 20-22g body weight, male athymic Bagg-albino/c (Balb/c) nu/nu mice 
were obtained from Charles River, Inc (Sulzfeld, Germany). All animal experiments were 
conducted according to german legislation for the protection of animals. 
 
4.2.9.2   A  mal’  housing conditions 
 
Animals were housed and maintained in laminar flow cabinets under specific pathogen-free 
conditions with free access to food and water. 
 
4.2.9.3   Anesthesia 
 
Mice were anesthetized with Ketaminhydrochlorid (Ketavet
® 
100mg/kg mouse body weight) and 
Xylazinhydrochlorid (Rompun
®
 5mg/kg mouse body weight). Normal saline, Ketavet and 
Rompun were mixed in a ratio of 1:1:1 (1 mL of each). The mixed anesthesia reagent was 
injected 50 uL intraperitoneally for each mouse. 
 
4.2.9.4   Orthotopic pancreatic tumor model and experimental treatment 
 
The operation was carried out in a sterile manner. A 1-cm left abdominal flank incision was 
made, the spleen was exteriorized, then 10
5
 isolated SP- or non-SP L3.6plGres cells were injected 
with a 1 ml syringe, 30G needle and a calibrated pushbutton-controlled device into the 
subcapsular region of the pancreas. There should be a fluid bleb without intraperitoneal leakage 
after a successful sub capsular intra-pancreatic injection. To avoid the cell suspension leaking 
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into the peritoneal cavity, a Q-tip was pressed lightly on the injection site for 30 seconds after the 
needle was pulled out of the liver. After injection of the tumor cells, the peritoneum and skin 
were closed with interrupted sutures of USP 4/0 Seralon. The procedure is shown in Figure IV.2. 
Mice in each group were blindedly categorized (Table IV.1).  After orthotopic injection, cell 
viability was measured with the trypan blue staining in order to control the therapeutic efficiency. 
Orthotopic tumor growth was monitored twice a week. Four weeks after the orthotopic 
implantation, therapy started: one treatment group was daily (every workday) intraperitoneal 
injection of low concentration of verapamil (200 uM, 0.5 mg/kg mice weight), another group 
was a relatively higher concentration of verapamil (10 mM, 25 mg/kg mice weight). On day 63 
after the injection all of the mice were sacrificed and examined for orthotopic tumor growth, 
lymph node and hepatic metastasis. The pancreas including the tumors and other organs were 
isolated, weighed and then used for the following Hematoxylin and Eosin (H&E) staining and 
immunohistochemistry. Detailed experimental time scheme is shown as Figure IV.3. 
 
 
Figure IV.2 Mice orthotopic pancreatic cancer model establishment 
 
A 0.8-1.0 cm left flank incision was conducted to expose the spleen, exteriorized the spleen 
softly with Q-tips, assisting further exposion of the pancrea. Tumor cell suspension was injected 
with a 1 ml disposable syringe, 30-gauge needle and a calibrated pushbutton-controlled 
dispensing device, into the head part of pancrea carefully, avoid of the intraperitoneal leakage. 
There is a transparent bleb after a successful sub capsular intrapancreatic injection. 
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Table IV.1 Experimental design for verapamil inhibition of SP tumorgenicity of pancreatic 
cancer 
 
 
 
Group 1: Balb/c nu/nu mice injected with SP cells isolated from L3.6plGres cells (n=5) 
Group 2: Balb/c nu/nu mice injected with NSP cells isolated from L3.6plGres cells (n=3) 
Group 3: Balb/c nu/nu mice injected with SP cells isolated from L3.6plGres cells and treated with 
relatively higher concentration of verapamil (10mM, 25mg/kg mice weight) (n=3, one died in the 
orthotopic operation) 
Group 4: Balb/c nu/nu mice injected with SP cells isolated from L3.6plGres cells and treated with 
relatively lower concentration of verapamil (200 uM, 0.5mg/kg mice weight) (n=4) 
 
 
 
Figure IV.3 Experimental schedule of the tumor model and the experimental treatment.  
FACS sorting for Group 1-4 was sequentially carried out during the first 1-3 days. L3.6plGres -SP 
cells induced palpable tumors one month after injection. Daily verapamil treatment was started 
on day 28 sequentially follow the injection. All the mice were sacrificed on day 63. 
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4.2.10   Histology 
 
4.2.10.1   Hematoxylin Eosin (H&E) staining 
 
All tumors from the in vivo experiments were formaldehyde-fixed and embedded in paraffin 
wax. Then 3-4 μm serial sections were generated. Tissues were deparaffinized in xylene, and 
rehydrated in a graded series of ethanol. After 5-8 minutes in Mayers Haematoxylin immersion, 
the sections were washed for 8 minutes with warm running water. Then the sections were 
immersed several seconds in Millipore water and stained with 0.1% Eosin solution for 2 minutes. 
After dehydration with graded series of ethatnol, the sections were mounted with Kaiser’s 
glycero gelatine and sealed with coverslips. 
 
4.2.10.2   Immunohistochemistry (staining for Ki67, CD31 and TUNEL) 
 
Formaldehyde-fixed and paraffin-embedded tissues were serially sectioned at 3 μm and allowed 
to dry overnight in 37℃ incubator. Sections were deparaffinized in xylene followed by a graded 
series of ethanol (100%, 95%, 80%) and rehydrated in phosphate-buffered solution, pH7.5. 
Paraffin-embedded tissues were used for Ki67 proliferation index assay, microvascular density 
analysis (CD 31 antibody) and TUNEL assay.  TUNEL assay was carried out with in situ cell 
death detection kit, Fluorescein (Roche Diagnostics GmbH, Mannheim, Germany) and closely 
followed its instruction, with a DAPI nuclear counterstaining. The antibodies used for the other 
paraffin-embedded tissues included monoclonal rabbit anti-Ki67 antibody (ab 16667, Abcam, 
UK) and polyclonal rabbit anti-CD31 (ab 28364, Abcam, UK), the primary antibodies were 
diluted in PBS containing 3% bovine serum albumin (BSA). In addition, the slides were treated 
for 20 minutes with blocking solution (8% goat serum or rabbit serum in PBS with 3% BSA) 
before the primary antibody was applied. Endogenous peroxidase was blocked by incubation 
with 3% hydrogen peroxide (H2O2). Endogenous avidin and biotin were blocked using the 
Avidin/Biotin Blocking Kit (Vector, United States). 
Overnight incubation with the primary antibodies was followed by incubation with the respective 
biotinylated secondary antibodies (goat anti-rabbit, BA-1000, Vector, United States), and the 
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ABC reagent for signal amplification (Vectastain ABC-Peroxidase Kits, PK-4000, Vector, 
United States). Between incubation steps, the slides were washed in   S. 3,3’-diaminobenzidine 
(DAB, Dako, United States) was used to develop color. Slides were counter-stained with 
hematoxylin, and mounted in Kaisers Glycerinegelatine and coverlsips. 
For quantification of the staining intensity each index (Ki67 index, microvascular density CD31 
index and TUNEL apoptotic index) were evaluated in a blinded manner. Slides were observed 
under high/low magnification (200×/100×), areas presenting the highest density of Ki67 positive 
cells (nuclear with brown color) or nuclear TUNEL signals (nuclear with green fluorescence) 
were chosen and captured as photographs. These photographs were analyzed by Image-J 
program. Each index in all groups was evaluated with 3 fields and data analyzed as mean 
positive signal (Ki67-positive cells, microvessels numbers, cells with strong FITC-fluorenscence) 
of these 3 fields. Necrotic tumor cells were excluded from the cell count. 
 
4.2.11   Statistical analysis 
 
Statistical evaluation was performed using the paired student’s t-test or ANOVA test (Microcal 
Origin) with p < 0.05 considered to be statistically significant. (p<0.05 mar ed as ‘&’; p<0.01 
mar ed as ‘#’; p<0.001 mar ed as ‘*’; p<0.0001 marked as ‘**’).  raphPad Prism® 5.0 or 
Microsoft excel 2010 softwares were used to generate graphs and tables. 
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V   Results 
 
5.1   In vitro part 
 
5.1.1   Gemcitabine induced morphological change of L3.6pl cells 
 
We cultivated the human pancreatic adenocarcinoma cell line L3.6pl continuously with 
gemcitabine, starting at 0.5 ng/ml up to 100ng/ml to develop a gemcitabine-resistant cell line 
(L3.6plGres). The 24h IC50 significantly increased from 6.1ng/ml ±0.9 (L3.6pl) to 498.8ng/ml 
±3.2 (L3.6plGres) (L3.6pl vs. L3.6plGres p<1E
-9
). Besides, the morphology of L3.6plGres cells 
gradually changed into large, fibroblastoid tumor cells (Figure V.1), while L3.6pl cells without 
treatment kept its original major round shape. 
 
 
A) L3.6pl  (100×)                                                          
 
 
 
 
 
 
 
 
 
Figure V.1 Cell image of L3.6pl and 
L3.6plGres following gemcitabine 
treatment.  
 
A)  parental L3.6pl cells: small and round 
cells with some irregular relatively larger 
cells;  
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B) L3.6plGres (30days after gemcitabine  
treatment, 100×) 
  
 
C) L3.6plGres (60days after gemcitabine  
treatment, 100 ×) 
  
  
5.1.2   Identification and characterization of SP cells in pancreatic cell lines  
 
5.1.2.1   Identification of SP cells using the Hoechst 33342 staining 
 
Both, L3.6pl and AsPC-1 cell lines were examined for the existence of SP cells. Verapamil 
hydrochloride, which blocks transporters of the ABC family and abrogates the ability to efflux 
the dye, served as control. These two cell lines contained a distinct proportion of SP cells. The 
percentage of SP cells increased from 0.9% ± 0.22 in L3.6pl to 5.38% ±0.99 in L3.6plGres cells 
following continuous gemcitabine treatment. The proportion of SP cells was diminished by 
Figure V.1. 
B) L3.6plGres cells after treatment with 
gemcitabine over 30 days: enlarged cell 
shape;  
 
 
 
 
Figure V.1. 
C) L3.6plGres cells after treatment with 
gemcitabine over 60 days: the majority of 
L3.6plGres cells have changed their 
morphology into a fibroblastoid type with 
loss of polarity, increased intercellular 
separation and pseudopodia, while an 
extreme minority of small round cells 
interspersed inside. 
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verapamil hydrochloride (Figure V.2). For each re-analysis of all the cell lines by FACS, the 
proportions of SP and NSP cells (Non-SP cells) were comparable to the intial distribution ratio 
of both subpopulations. Isolated NSP cells of L3.6pl or AsPC-1 rarely regenerate SP and NSP 
subpopulations. 
 
Figure V.2  Identification of SP cells using the Hoechst 33342 staining 
A. L3.6pl & L3.6plGres 
 L3.6pl 
 
 Verapamil              -                                                                +   
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L3.6plGres 
 
Verapamil              -                                                                 +   
 
B. AsPC-1 
AsPC-1 
 
Verapamil              -                                                                 + 
 RESULTS 
 
41 
 
A). Proportion of SP cells in L3.6pl (0.9% ± 0.22) compared to L3.6plGres cells (5.38% ± 0.99). 
Using verapamil, an ABC family drug-efflux blocker, the percentage of SP cells was 
significantly reduced to 0.16% ± 0.11(L3.6pl versus L3.6pl + verapamil, p < 5E
-10
); B). SP cells 
were identified in AsPC-1 cell line with 21.35% ± 3.48. Verapamil again induced a significant 
reduction of SP cells down to 3.56% ± 0.87(AsPC-1 versus AsPC-1 + verapamil, p < 5E
-10
). 
Note: Data are presented as mean ± standard deviation. 
 
5.1.2.2   L3.6plGres-SP cells were more resistant to gemcitabine than L3.6plGres-
NSP cells 
 
We tested the effect of gemcitabine treatment on L3.6plGres cells. SP and NSP cells were sorted 
out of L3.6plGres and treated with different concentrations of gemcitabine for 24 hours 
demonstrating that L3.6plGres SP cells were more resistant to gemcitabine than NSP cells (Figure 
V.3). 
 
 
 
 
 
Figure V.3 L3.6plGres-SP cells were more resistant to gemcitabine than L3.6plGres-NSP cells 
 Immediately after FACS sorting, SP as well as NSP cells from L3.6plGres were seeded into 96- 
well plates to cultivate overnight. Increasing concentrations of gemcitabine were applied for 24 
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hours. L3.6plGres-SP cells maintained their gemcitabine resistance compared to NSP cells with 
increasing doses of gemcitabine (p # < 0.01, p ** < 0.0001). 
5.1.2.3    L3.6plGres-SP cells exhibit stronger colony formation ability 
 
Since the percentage of L3.6pl SP cells is low, it was difficult to harvest enough cell samples by 
FACS for further analyses, so in part we took L3.6plGres cells with enriched SP cells as compared 
to the original L3.6pl cell line with less SP cells. Under this condition, we compared the colony 
formation ability between L3.6plGres and L3.6pl to support our hypothesis that SP cells have stem 
cell characteristics. The colony formation assay showed that L3.6plGres cells have significant 
higher colony formation ability than L3.6pl cell lines (Figure V. 4). 
 
Figure V.4 L3.6plGres-SP cells exhibit stronger colony formation ability 
 A).    
 
 
 
 
 
 
 
 
 
 
 
 
L3.6pl 
 
 
 
 
 
L3.6plGres 
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B). 
 
 
A). 500 single cells/well were seeded evenly into the 6-well plates with normal D-MEM culture 
medium and cultivated up to be  macroscopic visible colony(each colony composed of at least 50 
cells). The colonies were stained with crystal violet and counted. The upper three wells were 
seeded with L3.6pl cells, while the lower three wells were seeded with L3.6plGres cells.  
B). L3.6plGres can form more colonies per 500 single cells than L3.6pl (p #< 0.01). 
 
 
5.1.3   Effects of verapamil on pancreatic cancer cells 
 
As we stated above for the Hoechst 33342 staining assay, verapamil acts as a negative control 
since it can eliminate SP cells by effluxing the dye (shown in Figure V.2.A & B). To investigate 
if verapamil alone can act as a potential treatment for pancreatic cancer cells, especially 
pancreatic cancer SP cells, we analyzed the colony formation and cell viability with verapamil 
intervention on pancreatic cancer cells. 
 
5.1.3.1   Verapamil can inhibit the colony formation ability of L3.6pl and 
L3.6plGres  
 
24h verapamil treatment was carried out after the cells have already firmly attached to the plate 
and formed small cell masses (less than 50 single cells), which were visible under the 
 RESULTS 
 
44 
 
microscope. In consistence with Figure V.4.A, L3.6plGres maintained stonger colony formation 
ability than L3.6pl even with the treatment of verapamil. The inhibitory effect of verapamil on 
colony formation was dose independent on both cell lines: L3.6pl and L3.6plGres (Figure V.5). 
 
Figure V.5 Verapamil can inhibit the colony formation ability of L3.6pl and L3.6plGres     
                                 
  
 
Verapamil (uM) 0    50  100 
Two different concentrations of verapamil were used for both cell lines L3.6pl and L3.6plGres.  
L3.6plGres cells formed much more colonies than L3.6pl under each equal treatment condition 
(verapamil 0, 50 uM, 100 uM). At the concentration 100 uM, both cell lines formed less colonies 
than with 50 uM, than the controls without treatment.            
 
 
5.1.3.2   Verapamil alone can effectively inhibit viability of L3.6plGres and 
AsPC-1 SP cells in vitro 
 
We compared the anti-proliferative effect of verapamil on L3.6pl- and L3.6plGres cells as well as 
AsPC-1-SP and -NSP cells. 
All the above-mentioned cell lines demonstrated concentration dependent effects on cell viability 
following increasing doses of verapamil. Interestingly, under the same concentration of 50 uM, 
 
 
L3.6pl 
 
 
 
 
 
L3.6plGres 
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100 uM, 150 uM, 200 uM, the L3.6plGres- and AsPC-1-SP cells were much more sensitive to 
verapamil than L3.6pl- and AsPC-1-NSP cells (Figure V.6). 
 
Figure V.6 Verapamil alone can effectively inhibit viability of L3.6plGres and AsPC-1 SP cells 
in vitro 
 
A) 
 
B) 
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A). Treatment of L3.6pl and L3.6plGres cells for 24 hours with increasing concentrations of 
verapamil led to a dose dependent significant reduction of cell viability in L3.6plGres cells, which 
was much more sensitive to verapamil than L3.6pl cells(p * < 0.001，p ** < 0.0001). 
B). FACS sorted SP and NSP AsPC-1 cells were seeded into 96-wells plates evenly overnight, 
then treated with increasing concentrations of verapamil. Cell viability was significantly reduced 
in AsPC-1-SP cells than AsPC-1-NSP cells (p ** < 0.0001). 
5.1.4   Pro-apoptotic effect of verapamil plus gemcitabine in both L3.6pl and 
L3.6plGres cells 
 
Many studies reported that calcium channel blockers and calmodulin inhibitors are thought to act 
by blocking efflux of standard anticancer drug from the cell
94, 95
. To investigate an additive or 
synergistic anti-tumor effect of verapamil and gemcitabine on pancreatic cancer cell lines, 
apoptotic cells were analysed by FACS. 
L3.6plGres-SP cells were treated seperately with verapamil (50 uM), gemcitabine (10 ng/ml) and 
verapamil (50 uM) combined with gemcitabine (10 ng/ml). The amount of apoptotic cells after 
combined treatment for 24 hours increased as well as dead cells, in contrast to treatment with 
verapamil and gemcitabine alone (Figure V.7).   
 
Figure V.7 The amount of apoptotic cells after combined treatment for 24 hours increased as 
well as dead cells 
 
                    Annexin FITC                                           Annexin FITC                                         Annexin FITC  
                    verapamil(50 uM)                          gemcitabine(10 ng/ml)       verapamil(50uM)+gemcitabine(10 ng/ml)        
  
Sorted L3.6plGres-SP cells were treated with verapamil (50 uM), gemcitabine (10 ng/ml), or 
verapamil (50 uM) combined with gemcitabine (10 ng/ml) for 24 hours, then stained with 
Annexin FITC, and analyzed with BD-LSRII flow cytometer and FlowJo software. 
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Compared to verapamil and gemcitabine treatment alone the proportion of apoptotic cells as well 
as dead cells was substantially higher after combined treatment. 
Afterwards, we analyzed the amount of apoptotic cells in L3.6pl and L3.6plGres using further 
detailed concentrations of gemcitabine while keeping the concentration of verapamil at 50uM. 
An additive effect regarding the amount of apoptotic cells could only be observed in L3.6pl cells, 
but not in the L3.6plGres cells (Figure V.8). 
 
Figure V.8 An additive effect regarding the amount of apoptotic cells could only be observed in 
L3.6pl cells, but not in the L3.6plGres cells 
A) 
 
 
B) 
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L3.6pl and L3.6plGres cells were treated over 24 hours with different concentrations of 
gemcitabine (10 ng/ml, 40 ng/ml, 100 ng/ml) alone, or in combination with verapamil (50 uM).  
A) Under combination therapy, the proportion of apoptotic L3.6pl cells increased in a dose 
dependent manner (p & < 0.05, p # < 0.01, p * < 0.001);  
B) The percentage of apoptotic L3.6plGres was only slightly increasing following combination 
therapy. 
 
 
5.1.5   Expression levels of drug transporter proteins on L3.6pl and L3.6plGres  
 
Since we could not observe an additive effect of gemicatbine and verapamil in particular in 
L3.6plGres cells, we analyze the expression levels of the two main drug transporter proteins P-gp 
and ENT1 by Western Blotting. Our results revealed that the expression of P-gp and ENT1 was 
substantially lower in L3.6plGres as compared to L3.6pl cells. After 24 hours treatment with 
different concentrations of verapamil, the expression of P-gp and ENT1 on both cell lines was 
almost the same as without treatment (Figure V.9). 
 
Figure V.9 Expression levels of drug transporter proteins on L3.6pl and L3.6plGres 
 
                                                     
             A      B       C        D      E        F      G       H 
The protein lysates from:  
 A) L3.6pl;  
 B) L3.6plGres;  
 C) L3.6pl treated with verapamil (50 uM) for 24 hours; 
P-gp	
	
ß-ac n	
	
	
ENT1	
	
ß-ac n	
  A							B						C								D								E										F							G										H	
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ß-actin 
 
 
ENT1 
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 D) L3.6pl treated with verapamil (100 uM) for 24 hours;  
 E) L3.6pl treated with verapamil (200 uM) for 24 hours;  
 F) L3.6plGres treated with verapamil (50 uM) for 24 hours;  
 G) L3.6plGres treated with verapamil (100 uM) for 24 hours;  
 H) L3.6plGres treated with verapamil (200 uM) for 24 hours.  
The results indicate that the expression of P-gp in L3.6plGres cell line was lower than in L3.6pl 
cells.  
 
 
5.2   In vivo part 
 
5.2.1   Verapamil can effectively inhibit tumor growth induced by L3.6plGres-
SP cells in vivo 
   
 
L3.6plGres-SP and NSP cells were injected into the pancreas of athymic Balb/c nu/nu mice and 
subdivided in the following four groups: 1) L3.6plGres-SP group (5 mice), 2) L3.6plGres-NSP 
control group (3 mice); 3) L3.6plGres-SP treatment group with high concentration of verapamil 
(25mg/kg, 10mM, 3 mice, one mouse died in the operation); 4) L3.6plGres-SP treatment group 
with low concentration of verapamil (0.5mg/kg, 200uM, 4 mice). Verapamil treatment was 
started 4 weeks after the orthotopic pancreatic cancer cell injection. 9 weeks after the cell 
injection, all of the mice were sacrificed. Tumors and other organs were harvested for 
immunohistochemistry assays.  
The macroscopic results demonstrated that L3.6plGres-SP cells have much stronger tumorigenic 
capacity than L3.6plGres-NSP cells. Verapamil treatment (low/high concentration) substantially 
inhibited tumor growth and metastasis formation as compared to the SP control group (Figure 
V.10). No side effects were observed in the verapamil treatment group, group 3&4.  
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Figure V.10 Verapamil can effectively inhibit tumor growth induced by L3.6plGres-SP cells in 
vivo 
 
A) 
 
 
B) 
  
C) 
Group L3.6plGres-SP L3.6plGres-SP+Verapamil 
L3.6plGres-
NSP 
  
0.5mg/kg 25mg/kg 
 Primary 
4/5 0/4 1/3 0/3 Tumor 
Liver 
2/5 2/4 0/3 0/3 metastasis 
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A), B), C) Verapamil treatment significantly inhibited tumor growth in a dose independent way. 
In the low concentration treatment group, there were no macroscopic tumors in four mice, 
however, and two mice had liver metastasis. In the high concentration treatment group, there 
were no metastasis in all three mice, but one mouse presented with a small pancreatic tumor. 
5.2.2   Immunohistochemical analysis of L3.6plGres-SP following verapamil 
treatment  
 
Immunohistochemical stainings were carried out measuring the proliferation index, 
microvascular density and apoptosis of the pancreatic tumors in the L3.6plGres-SP control group 
and verapamil treatment groups (Figure V.11). The median percentage of Ki67+ proliferating 
cells within the tumors of the verapamil treatment group did not differ significantly from that of 
the L3.6plGres-SP group, however, verapamil treatment can limit the Ki67 index to a relatively 
constant range.  The amount of apoptotic cells was much more pronounced in the verapamil 
treatment group as compared to the L3.6plGres-SP group. The microvascular density as measured 
by immunohistochemical staining against CD31 revealed increased angiogenesis in tumors of the 
L3.6plGres-SP group. H&E staining revealed large, pleomorph cells with hyperchromatic nuclei 
in the L3.6plGres-SP group. 
 
Figure V.11 Immunohistochemical analysis of L3.6plGres-SP following verapamil treatment 
A)  H&E staining 
 
                             SP                                                    SP + Verapamil 
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B) Ki67 index 
 
                               SP                                                    SP + Verapamil 
 
C) TUNEL index 
 
                             SP                                                    SP + Verapamil 
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D) Microvascular density 
 
                             SP                                                    SP + Verapamil 
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Tumors from L3.6plGres-SP group and L3.6plGres-SP verapamil treatment groups were paraffin-
embedded and sectioned for different immunohistochemical and H&E staining.  
 
A) In H&E staining images large, pleomorph cells with hyperchromatic nuclei can be 
observed in the L3.6plGres-SP group, even some cancer nests were interspersed, while the 
normal, round, light nuclei composed most of the tumor tissue in verapamil treatment 
group. 
B) Immunohistochemical staining against Ki67 are shown. Ki67+ signal are manifested by 
dark brown stained cells. The scatter plot of Ki67 index shows that the median percentage 
of Ki67+ proliferating cells within the tumors of verapamil treatment group did not differ 
significantly from that of the L3.6plGres-SP group, while the standard deviation of Ki67 
index in L3.6plGres-SP group is wider than the verapamil treatment group. 
C) TUNEL apoptosis staining is shown. Apoptic cells are stained with fluorescencent green. 
The scatter plot of the TUNEL index shows that the number of apoptotic cells in the 
verapamil treatment group is significantly higher than in L3.6plGres-SP group (p 
**<0.0001). 
D)  CD31 staining is shown. The organge stained portions in the images are endothelial cells 
lining the vessels following anti-CD31 labeling. The scatter plot of microvessel density 
 RESULTS 
 
55 
 
shows that the average microvessel density in the verapamil treatment group is 
significantly reduced compared to the L3.6plGres-SP group (p#<0.01). 
 
 
Both, the macroscopic and microscopic results demonstrate that L3.6plGres-SP cells have 
indeed stem cell capacity and that verapamil alone can effectively inhibit tumor growth 
which was induced by L3.6plGres-SP cells. 
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VI Discussion 
 
 
The existence of CSCs is receiving increasing interest particularly due to its potential use in the 
clinical routine. These cells have stem-like self-renewal and tumor initiation capacity and are 
believed to be responsible for recurrence due to their resistance to therapy. CSCs have been 
enriched by several techniques such as growth in serum-free defined media to induce sphere 
formation. The isolation was performed by expression of certain surface marker combinations, 
i.e. CD44+/CD24-/lin- for human breast cancers
68
, EpCAM
high
/CD44+/CD166+ for colorectal 
cancer
96
, CD34+/CD38- for acute myeloid leukemia, broadly used as a target for chemotherapy
97
, 
and Stro1+/CD105+/CD44+, a surface marker for bone sarcoma
98
. Another approach to identify 
the CSC subpopulation is isolation of SP cells because of their inherent ability to efflux a 
fluorescent dye as well as chemotherapy reagents
99
. In the last decades, SP cells have already 
been widely applied in various tumors and cancer cell lines as a CSC subpopulation, e.g. acute 
myeloid leukemia
100
, neuroblastoma
76
, melanoma
101
, ovarian cancer
102
, the C6 glioma cell 
line
103
, human retinoblastoma cell line
104
, human neuroblastoma cell lines
76
, various human 
gastrointestinal cancer cell lines
105
 and pancreatic cancer cell lines, such as  MIA PaCa2, PANC-
1, Capan-2, KP-1 NL and SW1990
80, 89, 106, 107
. However, litte information has been reported 
about SP cells in the human pancreatic cancer cell lines L3.6pl and AsPC-1. 
Here, we successfully identified the SP subtype cells in the three cell lines with the aid of 
Hoechst 33342 staining (Figure V.2). We were able to isolate and characterize SP cells from the 
highly metastatic pancreatic adenocarcinoma cell line L3.6pl, its chemotherapy resistant variant 
L3.6plGres and AsPC-1 cell line.  
In vitro, the SP-enriched L3.6plGres cell line was endowed with much stronger colony formation 
ability than its parental cell line L3.6pl (Figure V.4&V.5). Figure V.3 showed L3.6plGres-SP cells 
exhibiting higher gemcitabine chemotherapy resistance ability than L3.6plGres-NSP cells, which 
was another manifestion their stem cell property. 
In vivo, we obtained significantly larger primary pancreatic tumors and higher incidence of liver 
metastasis following orthotopic injection of L3.6plGres SP cells as compared to L3.6plGres NSP 
cells, which was another compelling evidence of the stem cell capacity of SP cells (Figure 
V.10.A & C). 
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During the acquisition of gemcitabine resistance some morphologic changes were gradually 
induced. Fibroblastoid cells with loss of polarity, increased intercellular separation and 
pseudopodia were in large quantity present in L3.6plGres (Figure V.1), which was consistent with 
the common phenomenon of Epithelial-to-Mesenchymal (EMT) transition. Emerging evidences 
demonstrates that molecular and phenotypic associations exist between chemotherapy resistance 
and the acquisition of an EMT-like cancer cell phenotypes
108-111
.  
The SP subtype cells play a major role in metastasis and chemotherapy resistance. SP cells might 
be related to chemotherapy resistance induced EMT. Some studies on pancreatic and breast 
cancer have already analyzed a potential relationship between chemoresistance induced EMT 
and CSCs
112
 
113, 114
, however, this hypothesis needs to be directly confirmed by further studies. 
 Goodell et al
73
 have demonstrated that the pumps responsible for Hoechst33342 efflux, which 
differentiates SP from NSP cells, were mainly contributed by transporter proteins of the ABC 
superfamily including MDR1/P-gp, ABCG2, and MRP, which are the key factors contributing to 
the development of tumor drug resistance
35-38
. Verapamil, the first generation P-gp inhibitor, has 
been reported to be able to block the dye efflux activity and reverse partially the resistance 
caused by P-gp
31, 54, 115
, which results in an increase of drug uptake by tumor cells
54
. We also 
conducted Hoechst 33342 staining following the  oodell’s protocol where verapamil usually 
acts as a negative control since it can eliminate the SP cells in L3.6pl, L3.6plGres, and AsPC-1 
cells shown in Figure V.2.  
Our hypothesis was that verapamil could be a specific SP inhibitor and therefore a novel therapy 
against pancreatic cancer stem cells. Our studies revealed that verapamil alone can inhibit cell 
proliferation in vitro in a dose-dependent manner. Interestingly, verapamil inhibited SP cells 
more than NSP cells in both human pancreatic cell lines: L3.6plGres and AsPC-1 (Figure V.6), 
while in vivo verapamil can effectively prevent tumor growth induced by L3.6plGres-SP cells 
(Figure V.10).  
 Our demonstration of the inhibitiory effect of verapamil on pancreatic cells is in agreement with 
a few earlier reports that verapamil inhibits proliferation and promotes differentiation in human 
promyelocytic HL-60 cells
116
, produces a growth inhibiting effect on human colonic tumor 
cells
117
 and has an antiproliferative effect alone on the human brain tumor cells in vitro
118
. 
Among the human brain tumor cells, William Schmidt et al. showed a reversible, 
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antiproliferative action of verapamil on human medulloblastoma, pinealoblastoma, glioma, and 
neuroblastoma tumor lines from pediatric patients
118
. 
 We found that SP cells in L3.6plGres and AsPC-1 cell lines are more sensitive to verapamil than 
NSP cells, which was consistent with our hypothesis. However, as we compared the protein 
expression level of P-gp between L3.6pl and L3.6plGres, L3.6pl contained a higher expression 
level of P-gp than L3.6plGres, and verapamil treatment did not affect the expression level at all 
(Figure V.9). This result was in accordance with Jensen et al
119
 who observed that some small-
cell lung cancer (SCLC) cells with P-gp high expression were more sensitive to gemcitabine and 
the structurally related deoxycytidine analogue 1-β-D-arabinofuranosylcytidine (cytarabine, ara-
C). Sheng Zhou et al. demonstrated that P-gp is not required for the SP phenotype in 
hemotopoietic stem cells
75
, other scientists showed that the liver and the bone marrow of MDR1 
knockout mice present normal numbers of SP cells in primitive hematopoietic cells
120
. Besides, 
Sugawara et al. and Bernard et al. both failed to demonstrate P-gp expression in pancreatic 
cancer tissues
43, 44， therefore, clinical significance of MDR1/P-gp expression in human 
pancreatic cancer stayed controversial. Obviously, the low protein expression level of P-gp in 
L3.6plGres cells is not the explanation for the high sensitivity of SP cells to verapamil. Some 
researchers explained this effect with the anti-proliferative and P-gp inhibitiory mechanisms of 
verapamil. One of these controversial mechanisms may include the phospholipid/Ca
++
-dependent 
PKC (protein kinase C) in MDR
121
, several studies reported an increase in PKC activity in cells 
with an overexpression of P-gp or MRP
122, 123
, but whether phosphorylation of P-gp modulates 
the pump function is still debatable
123-126
.  
 Another important issue is that gemcitabine is a deoxycitidine analogue that is activated by 
deoxycytidine kinase (dCK) to its monophosphate and subsequently to its triphophate dFdCTP, 
which is incorporated into both RNA and DNA, leading to DNA damage. Since dCK may be 
phosphorylated by PKC and exhibits a higher activity in the phosphorylated state
127
, PKC 
activation might play a role in the collateral sensitivity to gemcitabine in P-gp high expressing 
cells. 
Both of our in vitro apoptosis assay results (Figure V.7 & V.8.) and in vivo 
immunohistochemistry analysis (Figure V.11.C) showed pro-apoptotic effects of verapamil. The 
enhancement of apoptotic tumor cells under therapy with verapamil may be explained by the fact 
that verapamil as a calcium channel antagonist, interferes with intracellular signaling pathways
117, 
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128-130
. Calcium ions (Ca
2+
), a cellular messanger that control aspect of cell and tissue physiology, 
can be turned into death signals when delivered at the wrong time and place
131, 132
. The use of 
calcium antagonists may break the mobile equilibrium between intracellular and extracellular 
Ca
2+
, which causes the Ca
2+ 
that is stored in the cell to be released into the cytoplasm, resulting 
in an increase of the intracellular concentration of Ca
2+117
. Since Ca
2+
 is toxic at high 
concentrations a low Ca
2+ 
concentration must be maintained in the cytoplasm
133
, therefore 
verapamil might induce cell apoptosis though destroying this Ca
2+
 balance. 
Other members of the ABC superfamily may contribute to the SP induced chemotherapy 
resistance and trigger apoptosis in pancreatic cancer as well. Recently, investigators found 
verapamil and its derivative can trigger apoptosis though glutathione (GSH) extrusion by 
MRP1
62
, while many substrates of MRP1 are conjugated to reduced glutathione. Extrusion of 
GSH out of the cells will cause oxidative stress, which is a universal well-recognized trigger for 
apoptosis
134
.   
We applied two different doses of verapmil for intraperitoneal treatment of SP induced 
pancreatic tumors, one is 0.5 mg/kg/d, 200 uM, this concentration design was based on the in 
vitro proliferation assay (Figure 5 A.), which showed that the inhibition rate of L3.6pl and 
L3.6plGres can be controlled above 50%; the other concentration is relatively high, 25 mg/kg/d, 
10 mM, which referred to clinical combination treatment doses for pancreatic cancer patients (20 
mg/d for a 70 KG BW patient
65
) and former publications of verapamil treatment in mouse 
tumors
135, 136
. 
 The last point needed to elucidate is that, the additive anti-cancer effect of verapamil and 
gemcitabine in pancreatic cancer. Although this calcium channel blocker is well known for its 
ability to enhance cytotoxicity when used in combination with the other chemotherapy reagents, 
such as anthracyclines
56, 137
, paclitaxel
42
, epipodophyllotoxins
138
 and melphalan
94
, little is known 
about the effects of verapamil used alone and in combination with the tranditional pancreatic 
cancer chemotherapy reagent gemcitabine. In our study, we identified combined pro-apoptotic 
effects of verapamil and gemcitabine on L3.6pl rather than L3.6plGres using the same treatment 
conditions. In Figure V.9 we demonstrated that the expression level of ENT1, which is the major 
uptake transporter of gemcitabine was extremely low in L3.6plGres cells as compared to L3.6pl 
cells. The absence of ENT1 has already been clinically associated with reduced survival in 
patients with gemcitabine treated pancreatic adenocarcinoma
52
. 
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In conclusion, our study revealed that verapamil acts on pancreatic cancer cells in vitro most 
likely by inducing apoptosis of stem like SP cells in L3.6pl, L3.6plGres and AsPC-1 cells. 
Verapamil can significantly inhibit pancreatic cancer tumor growth in vivo most likely by 
targeting stem like side population cells, which could provide evidences for a new clinical 
feature of this ‘old’ reagent. However, further investigation should be carried out to make clear 
the exact mechanisms of verapamil on SP cells. 
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VII Summary  
  
 
 SP subtype cells can be clearly identified by Hoechst 33342 assay. 
 SP subtype cells were enriched in the gemcitabine induced resistant cell line 
L3.6plGres. 
 L3.6plGres-SP cells were characterized as CSCs by exhibiting stronger colony 
formation capacity, chemotherapy resistance, and higher tumorigenicity. 
 Verapamil alone can effectively inhibit L3.6plGres-SP and AsPC-1-SP in 
vitro, and prevent tumor growth induced by L3.6plGres-SP in vivo. 
 Verapamil can induce apoptosis effect in pancreatic cancer cells, however, 
when combined with gemcitabine, an additive or synergistic pro-apoptotic 
effect cannot be generated in all the cell lines in our study. 
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VIII Zusammenfassung 
 
 
 Side population (SP) Zellen können eindeutig durch die Verwendung des 
Hoechst 33342 Farbstoffs durch FACS Sorting identifiziert und analysiert 
warden.  
 Side population (SP) Zellen werden durch Induktion einer Gemcitabine-
Resistenz in L3.6plGres angereichert. 
 L3.6plGres-SP Zellen können als eine Subpopulation von Tumorstammzellen 
charakterisiert werden, da sie eine deutliche Fähigkeit zur Clone-Formierung 
in vitro, Chemotherapie-Resistenz und eine deutlich erhöhte Tumorigenität 
in vivo haben.  
 Verapamil allein hemmt das Tumorzellwachstum von L3.6plGres-SP und 
AsPC-1-SP Zellen in vitro. Des Weiteren führt es zu einer signifikanten 
Abnahme des orthotopen Tumorwachstums von L3.6plGres-SP Zellen in vivo. 
 Verapamil führt zur Apoptose von Pankreastumorzellen, allerdings ist ein 
additive oder synergistischer pro-apoptotischer Effekt in Kombination mit 
Gemcitabine in vitro nicht für alle Zellinien nachweisbar.  
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IL interleukin 
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